ADVENT at ISDS 2023: Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch

Highlights from the ADVENT symposium at the Inflammatory Skin Disease Summit (ISDS) 2023 exploring the role of type 2 inflammation in atopic dermatitis.

Lisa Beck +2 more

See post-event materials

Past event

16November2023

Location

Aula der Wissenschaften

Wollzeile 27a A-1010 Vienna Austria

Learning objectives

Review the latest evidence on how type 2 inflammation drives skin barrier dysfunction in AD
Discuss the evidence illustrating how type 2 inflammation affects the skin microbiome in AD
Explore the role of type 2 inflammation in neuroimmune axis dysregulation in AD

Description

At the ADVENT symposium at the 2023 Inflammatory Skin Disease Summit entitled “Navigating Recent Scientific Advances in Atopic Dermatitis: Skin Barrier Dysfunction, Dysbiosis, and Itch”, experts Lisa A. Beck, MD (University of Rochester Medical Center, USA); Robert Bissonnette, MD (Innovaderm Research Inc., Canada); and Gil Yosipovitch, MD (University of Miami, USA) discussed the latest advances in understanding how type 2 inflammation drives skin barrier dysfunction, dysbiosis and itch in atopic dermatitis (AD).

Location

Aula der Wissenschaften

Wollzeile 27a A-1010 Vienna Austria

Speakers

Dermatology

Lisa Beck

Goldsmith Professor of Dermatology, University of Rochester Medical Center, New York, United States.

Dermatology

Robert Bissonnette

President of Innovaderm Research, Montréal, Quebec, Canada

Dermatology

Gil Yosipovitch

Professor and Stiefel-endowed Chair of Medical Dermatology at the Dr. Phillip Frost Department of Dermatology at the Miller School of Medicine at the University of Miami; Director of the Miami Itch Center, Florida, US

Related resources

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

Dermatology

2 min

videoanimation

Atopic Dermatitis (AD) is a Type 2 Inflammatory Disease

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: NorwayChange country/region